Clinical trials Clinical trials BAX855 PROPEL (Haemophilia A) Project Title BAX 855 PK-guided Dosing (PROPEL). Official Title Phase 3, Prospective, Randomized, Multi-center Clinical Study Comparing the Safety and Efficacy of BAX 855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects With Severe Hemophilia A. Project Summary This project aims to: To compare the efficacy and safety of pharmacokinetic (PK)-guided treatment with BAX 855 targeting FVIII trough levels of 1-3% and approximately 10% (8-12%). To further characterize pharmacokinetic (PK) and pharmacodynamic (PD) parameters of BAX 855. Blood Disorder Hemophilia A Patient Recruitment Details Patient recruitment status: Closed Number of Patients (globally) 135 participants. Back to Archived Projects...